Brian Piper, M.B.A


Chief Financial Officer

Brian Piper, M.B.A currently serves as Chief Financial Officer at Prelude Therapeutics. Mr. Piper joined Prelude in 2019 and has over 25 years of experience in corporate healthcare finance, covering a wide span of financial and operational activities. Prior to joining Prelude, Mr. Piper served as Chief Financial Officer and Corporate Secretary at Aevi Genomic Medicine (later acquired by Cerecor, Inc.). Prior to his time with Aevi, Mr. Piper served as Vice President, Finance and Investor Relations at Medgenics, Inc. from 2014 to 2016, and prior to Medgenics, had a 13- year career at Shire Pharmaceuticals (later acquired by Takeda Pharmaceutical Company Limited), holding key roles in Investor Relations, Corporate Venture Capital, and numerous additional financial roles, including two years spent in Dublin, Ireland establishing Shire’s geographic expansion strategies. Early in his career, Mr. Piper also spent time with Celera Genomics and Otsuka Pharmaceuticals, Inc. Mr. Piper received his B.B.A. from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.